Magnetic resonance imaging in multiple sclerosis.
Conventional magnetic resonance imaging (MRI) techniques acquire signal mainly from differences in relaxation properties and density of free water protons. Thus, the sensitivity in depicting lesions is high but pathological specificity is poor. Efforts are being made to increase the diagnostic power of MRI; better correlation with the clinical presentation and the use of better MRI criteria have increased the specificity of the conventional T2 sequences. New sequences, such as fast spin echo, turbo spin echo (TSE) or those derived from inversion recovery (fluid attenuated inversion recovery), have improved the detection of lesions. Acute phase monitoring focuses on changes in disease activity (new, recurring, enlarging, gadolinium-enhancing lesions) and chronic phase monitoring allows appreciation of the burden of the disease. However, MRI is considered as a secondary outcome measure in phase III trials because of insufficient correlation with the clinical disability. There is a continuing search for techniques that correlate better with clinical measures of the disease, such as the quantification of 'black holes' on T1-weighted images or the cerebral and spinal atrophy. The basic aspects of the pathological lesions in multiple sclerosis such as oedema, membrane disruption, demyelination, gliosis, cellular infiltration and axonal loss, can be studied more precisely by the new magnetic resonance techniques, which should better describe the actual clinical impact of the destructive process. In the past year the importance of axonal loss has simultaneously been confirmed by magnetic resonance spectroscopy and pathological findings. However, magnetization transfer imaging, magnetic resonance diffusion imaging and functional MRI are under intensive investigation for a better analysis of these different factors that impact on the reversibility of the patients disability.
Clanet
M
M
Fédération de Neurologie, CHU Toulouse Purpan, Toulouse, France.
Berry
I
I
D004058:Diffusion; D005682:Gadolinium; D006801:Humans; D008279:Magnetic Resonance Imaging / Q000379:methods*; D009682:Magnetic Resonance Spectroscopy; D009103:Multiple Sclerosis / Q000175:diagnosis*; D011237:Predictive Value of Tests; D011379:Prognosis
D005682:Gadolinium